PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>GHRP-6
Preclinical WADA prohibitedGH / growth factors

GHRP-6

The first-generation hexapeptide GH secretagogue from which the GHRP family grew. It stimulates GH release and, notably, hunger via ghrelin-receptor agonism.

CompoundGHRP-6
CategoryGH-releasing peptide
ClassGrowth Hormone and Growth Factors
Evidence tierPreclinical
WADA statusProhibited in sport (or falls under a prohibited class) — see the WADA reference table
Sold on this siteNo — this is a reference database

Overview

This entry covers GHRP-6, a gh-releasing peptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

The first-generation hexapeptide GH secretagogue from which the GHRP family grew. It stimulates GH release and, notably, hunger via ghrelin-receptor agonism.

Mechanism of Action

GHRP-6 activates the ghrelin receptor, producing GH pulses and appetite stimulation — the orexigenic effect being an expected pharmacological consequence rather than a side effect in the usual sense.

Research and Evidence

Early human pharmacology studies characterized its GH response; no approved indication resulted. Its hunger effect made it less attractive than more selective successors.

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

Documented effects include increased appetite, and mild cortisol/prolactin elevation. Prohibited in sport under growth hormone releasing factor rules.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of GHRP-6?

GHRP-6 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

Is GHRP-6 an approved medicine?

No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for GHRP-6?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for GHRP-6 studies. [source]
  2. WADA Prohibited List. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement